Cell-free exozyme systems are revolutionizing how we produce medicines and nutraceuticals
Living cells are not designed to be chemical factories. Over $8-12 billion in capital was lost when companies discovered the fundamental limitations.
Cells are programmed to prioritize survival, not industrial production. They naturally resist producing foreign compounds in high concentrations.
Living cells mutate to shed engineered pathways. Over generations, they "silence" synthetic genes, leading to complete loss of production.
Up to 90% of feedstock energy is consumed just keeping the cell alive, leaving minimal resources for actual product synthesis.
Many valuable medicines and nutraceuticals are toxic to cells at high concentrations, creating an insurmountable production ceiling.
Cells produce thousands of different molecules. Isolating the target product from this biological mixture is complex, expensive, and often breaks the business case.
Moving from lab to industrial scale is notoriously risky. What works in a 1-liter flask often fails in a 100,000-liter fermenter.
By removing the cell, we unlock unprecedented precision, scalability, and sustainability.
Direct control over every variable: pH, temperature, cofactors. Predictable, repeatable results.
Chemical engineering principles ensure gram-scale results translate to ton-scale production with high fidelity.
No massive sterilization, cooling, or complex waste management. Dramatically lower environmental footprint.
Simplified purification. The target product is the primary component, not buried in cellular noise.
From concept to gram-scale production in just 5 months. What would take years with cell-based methods.
| Metric | eXoZymes NCT | Traditional Synbio |
|---|---|---|
| Development Time | 5 Months | 2–5 Years |
| Product Purity | >99% | Often requires extensive post-processing |
| Yield | 96% (Near-perfect conversion) | Typically 10–30% due to metabolic diversion |
| Scale-up Factor | 100x with near-perfect fidelity | High risk of failure or yield drop |
eXoZymes integrates discoveries from four recent Nobel laureates into a single platform.
Frances H. Arnold's strategies enhance enzymes to become robust exozymes.
Emmanuelle Charpentier & Jennifer Doudna's gene editing precisely engineers enzyme expression.
Carolyn R. Bertozzi, Morten Meldal & K. Barry Sharpless' principles define our cell-free approach.
David Baker, Demis Hassabis & John Jumper's AI methods optimize exozyme function.
Our exozyme approach is validated by multiple publications in peer-reviewed high-impact journals.
Protein Science (2014)
A synthetic biochemistry system for the in vitro production of isoprene from glycolysis intermediates
Nature Communications (2014)
A synthetic biochemistry molecular purge valve module that maintains redox balance
Nature Chemical Biology (2016)
A synthetic biochemistry module for production of bio-based chemicals from glucose
Nature Communications (2017)
A synthetic biochemistry platform for cell free production of monoterpenes from glucose
Nature Chemical Biology (2017)
A molecular rheostat maintains ATP levels to drive a synthetic biochemistry system
Nature Communications (2019)
A cell-free platform for the prenylation of natural products and application to cannabinoid production
Cell - Trends in Biotechnology (2020)
Synthetic Biochemistry: The Bio-inspired Cell-Free Approach to Commodity Chemical Production
Nature Chemical Biology (2020)
A bio-inspired cell-free system for cannabinoid production from inexpensive inputs
GEN Biotechnology (2025)
Exozymes for Biomanufacturing: Toward Clarity and Precision in the Cell-Free Space
eXoZymes is pioneering a faster, cleaner, and more precise way to manufacture the essential chemicals of tomorrow.